J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on December 1, 2003

Papers In Press, published online ahead of print October 16, 2003
J. Lipid Res., doi:10.1194/jlr.M300253-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M300253-JLR200v1
44/12/2374    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olivieri, O.
Right arrow Articles by Corrocher, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olivieri, O.
Right arrow Articles by Corrocher, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on June 11, 2003
Revised on September 3, 2003
Accepted on October 10, 2003

Apolipoprotein C-III, metabolic syndrome and risk of coronary artery disease

Oliviero Olivieri, Antonella Bassi, Chiara Stranieri, Elisabetta Trabetti, Nicola Martinelli, Francesca Pizzolo, Domenico Girelli, Simonetta Friso, Pier Franco Pignatti, and Roberto Corrocher

Department of Clinical Experimental Medicine, University of Verona, Verona 37134

Corresponding Author: oliviero.olivieri{at}univr.it

Apolipoprotein C-III is a marker of (TG) -rich lipoproteins, which are often increased in metabolic syndrome (MS). The T–455C polymorphism in the insulin responsive element region of APOC3 gene influences TG and apo C-III levels. The aim of the present study was to evaluate the contribution of apo C-III levels and T-455C polymorphism in affecting coronary artery disease (CAD) risk in MS patients. We studied 873 patients, 549 with angiographically documented CAD, and 251 with normal coronary arteries. Patients were classified also for having or not the metabolic syndrome (MS, n=270; MS-free, n=603) according to well established criteria. Lipids, insulin, apolipoproteins levels as well as the APOC3 T–455C genotypes were evaluated. Apo C-III levels were significantly increased in MS patients and the probability of having MS was correlated with increasing quartiles of apo C-III levels. Moreover, MS patients with CAD had significantly higher apo C-III levels than CAD-free MS patients. The carriership for –455C variant multiplied the probability of CAD in MS, in allele-specific way, and was associated with increased apo C-III and TG levels. Obesity was less frequent in MS carriers of the –455C allele than in MS non carriers (21.6% vs. 34.8%, p<0.05). In conclusion, APOC3 polymorphism has a relevant impact on CAD risk of MS patents, thus suggesting a role for apo C-III-rich lipoproteins metabolism in the pathophysiology of cardiovascular disease.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Pavlic, R. Valero, H. Duez, C. Xiao, L. Szeto, B. W. Patterson, and G. F. Lewis
Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans
Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1660 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Kawakami, M. Osaka, M. Tani, H. Azuma, F. M. Sacks, K. Shimokado, and M. Yoshida
Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction
Circulation, August 12, 2008; 118(7): 731 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Cardiovascular DiseaseHome page
S. Sookoian and C. J. Pirola
Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 37 - 47.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Grundy
Gamma-Glutamyl Transferase: Another Biomarker for Metabolic Syndrome and Cardiovascular Risk
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 4 - 7.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Kawakami, M. Aikawa, N. Nitta, M. Yoshida, P. Libby, and F. M. Sacks
Apolipoprotein CIII-Induced THP-1 Cell Adhesion to Endothelial Cells Involves Pertussis Toxin-Sensitive G Protein- and Protein Kinase C{alpha}-Mediated Nuclear Factor-{kappa}B Activation
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 219 - 225.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
E. A. Ruiz-Narvaez, Y. Yang, Y. Nakanishi, J. Kirchdorfer, and H. Campos
APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica
J. Lipid Res., December 1, 2005; 46(12): 2605 - 2613.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Bozzini, D. Girelli, O. Olivieri, N. Martinelli, A. Bassi, G. De Matteis, I. Tenuti, V. Lotto, S. Friso, F. Pizzolo, et al.
Prevalence of Body Iron Excess in the Metabolic Syndrome
Diabetes Care, August 1, 2005; 28(8): 2061 - 2063.
[Full Text] [PDF]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
M. Banning
Obesity: pathophysiology and treatment
The Journal of the Royal Society for the Promotion of Health, July 1, 2005; 125(4): 163 - 167.
[Abstract] [PDF]

Home page
 J. Lipid Res.Home page
G. Gerritsen, P. C. N. Rensen, K. E. Kypreos, V. I. Zannis, L. M. Havekes, and K. Willems van Dijk
ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression
J. Lipid Res., July 1, 2005; 46(7): 1466 - 1473.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Genoux, H. Dehondt, A. Helleboid-Chapman, C. Duhem, D. W. Hum, G. Martin, L. A. Pennacchio, B. Staels, J. Fruchart-Najib, and J.-C. Fruchart
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR{alpha}
Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1186 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen
Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats
J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J.-M. Guettier, A. Georgopoulos, M. Y. Tsai, V. Radha, S. Shanthirani, R. Deepa, M. Gross, G. Rao, and V. Mohan
Polymorphisms in the Fatty Acid-Binding Protein 2 and Apolipoprotein C-III Genes Are Associated with the Metabolic Syndrome and Dyslipidemia in a South Indian Population
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1705 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al.
Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction
Clin. Chem., February 1, 2005; 51(2): 360 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C.C. Shoulders, E.L. Jones, and R.P. Naoumova
Genetics of familial combined hyperlipidemia and risk of coronary heart disease
Hum. Mol. Genet., April 1, 2004; 13(90001): R149 - 160.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.